Incyte Remains Undervalued As Opzelura And Niktimvo Scale [Seeking Alpha]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Seeking Alpha
In my view, the key drivers of raised investor interest in Incyte are the strong performance of its ruxolitinib franchise. By the way, Incyte expects Opzelura sales to grow from $678.5 million in 2025 to $750-$790 million this year. And coupledwith significant progress in its tafasitamab and INCA033989, I continue tocover Incyte with a 'Buy' rating. jacoblund/iStock via Getty Images Since my last article in August, "Incyte: Wall Street Underestimates Strength of Ruxolitinib Portfolio," Incyte shares ( INCY ) are up 19.1%. Thus, it outperformed the S&P 500 [6.8% return] ( SPY ), as well as the so-called 'bellwether' for This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of LEGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company w
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Where is Incyte Corporation (INCY) Headed According to Analysts? [Yahoo! Finance]Yahoo! Finance
- Incyte (NASDAQ:INCY) was given a new $117.00 price target on by analysts at Barclays PLC.MarketBeat
- Incyte to Present at Upcoming Investor ConferencesBusiness Wire
- The Touchstone Dynamic Large Cap Growth Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Incyte (NASDAQ:INCY) had its price target lowered by analysts at Royal Bank Of Canada from $95.00 to $92.00. They now have a "sector perform" rating on the stock.MarketBeat
INCY
Earnings
- 2/10/26 - Beat
INCY
Sec Filings
- 2/19/26 - Form 144
- 2/10/26 - Form SCHEDULE
- 2/10/26 - Form 10-K
- INCY's page on the SEC website